[go: up one dir, main page]

WO2004078169A8 - Use of ep2 selective receptor agonists in medical treatment - Google Patents

Use of ep2 selective receptor agonists in medical treatment

Info

Publication number
WO2004078169A8
WO2004078169A8 PCT/IB2004/000553 IB2004000553W WO2004078169A8 WO 2004078169 A8 WO2004078169 A8 WO 2004078169A8 IB 2004000553 W IB2004000553 W IB 2004000553W WO 2004078169 A8 WO2004078169 A8 WO 2004078169A8
Authority
WO
WIPO (PCT)
Prior art keywords
facilitating
treating
hypertension
selective receptor
occurrence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IB2004/000553
Other languages
French (fr)
Other versions
WO2004078169A1 (en
Inventor
Alexander Angelo Constan
Prakash Raj Keshary
David Burton Maclean
Vishwas Madhav Paralkar
Doina Cosma Roman
David Duane Thompson
Timothy Michael Wright
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Products Inc
Original Assignee
Pfizer Products Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Products Inc filed Critical Pfizer Products Inc
Priority to EP04713611A priority Critical patent/EP1601351A1/en
Priority to BRPI0408061-0A priority patent/BRPI0408061A/en
Priority to AU2004216898A priority patent/AU2004216898A1/en
Priority to NZ541828A priority patent/NZ541828A/en
Priority to MXPA05009398A priority patent/MXPA05009398A/en
Priority to JP2006506276A priority patent/JP2006519250A/en
Priority to CA002518193A priority patent/CA2518193A1/en
Publication of WO2004078169A1 publication Critical patent/WO2004078169A1/en
Publication of WO2004078169A8 publication Critical patent/WO2004078169A8/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433—Thidiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

The present invention relates to methods of treating pulmonary hypertension, facilitating joint fusion, facilitating tendon and ligament repair, reducing the occurrence of secondary fracture, treating avascular necrosis, facilitating cartilage repair, facilitating bone healing after limb transplantation, facilitating liver regeneration, facilitating wound healing, reducing the occurrence of gastric ulceration, treating hypertension, facilitating the growth of tooth enamel or finger or toe nails, treating glaucoma, treating ocular hypertension, and repairing damage caused by metastatic bone disease using an EP2 selective receptor agonist.
PCT/IB2004/000553 2003-03-04 2004-02-23 Use of ep2 selective receptor agonists in medical treatment Ceased WO2004078169A1 (en)

Priority Applications (7)

Application Number Priority Date Filing Date Title
EP04713611A EP1601351A1 (en) 2003-03-04 2004-02-23 Use of ep2 selective receptor agonists in medical treatment
BRPI0408061-0A BRPI0408061A (en) 2003-03-04 2004-02-23 medical treatment using an ep 2 selective receptor agonist
AU2004216898A AU2004216898A1 (en) 2003-03-04 2004-02-23 Use of EP2 selective receptor agonists in medical treatment
NZ541828A NZ541828A (en) 2003-03-04 2004-02-23 Use of EP2 selective receptor agonists in medical treatment
MXPA05009398A MXPA05009398A (en) 2003-03-04 2004-02-23 Use of ep2 selective receptor agonists in medical treatment.
JP2006506276A JP2006519250A (en) 2003-03-04 2004-02-23 Use of EP2 selective receptor agonists in medical procedures
CA002518193A CA2518193A1 (en) 2003-03-04 2004-02-23 Use of ep2 selective receptor agonists in medical treatment

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US45188903P 2003-03-04 2003-03-04
US60/451,889 2003-03-04

Publications (2)

Publication Number Publication Date
WO2004078169A1 WO2004078169A1 (en) 2004-09-16
WO2004078169A8 true WO2004078169A8 (en) 2005-04-21

Family

ID=32962656

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2004/000553 Ceased WO2004078169A1 (en) 2003-03-04 2004-02-23 Use of ep2 selective receptor agonists in medical treatment

Country Status (14)

Country Link
EP (1) EP1601351A1 (en)
JP (1) JP2006519250A (en)
KR (1) KR20050105511A (en)
CN (1) CN1859903A (en)
AU (1) AU2004216898A1 (en)
BR (1) BRPI0408061A (en)
CA (1) CA2518193A1 (en)
CL (1) CL2004000412A1 (en)
MX (1) MXPA05009398A (en)
NZ (1) NZ541828A (en)
PL (1) PL378748A1 (en)
TW (1) TW200424176A (en)
WO (1) WO2004078169A1 (en)
ZA (1) ZA200506532B (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7196089B2 (en) 2003-01-29 2007-03-27 Asterand Uk Limited EP4 receptor antagonists
US7417068B2 (en) 2003-10-16 2008-08-26 Asterand Uk Limited EP4 receptor antagonists

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070270489A1 (en) * 2003-07-25 2007-11-22 Ono Pharmaceutical Co., Ltd. Remedy for Cartilage-Related Diseases
US8604055B2 (en) 2004-12-31 2013-12-10 Dr. Reddy's Laboratories Ltd. Substituted benzylamino quinolines as cholesterol ester-transfer protein inhibitors
CN101443006B (en) 2004-12-31 2012-10-10 雷迪美国治疗股份有限公司 Novel benzylamine derivatives as CETP inhibitors
US7915316B2 (en) 2005-08-22 2011-03-29 Allergan, Inc Sulfonamides
US7696235B2 (en) * 2005-08-29 2010-04-13 Allergan, Inc. EP2 receptor agonists for treating glaucoma
RU2425876C2 (en) 2006-03-24 2011-08-10 Чилдрен'З Медикал Сентер Корпорейшн Method of heamatopoietic stem cell growth modulation
RS20090002A (en) 2006-07-28 2010-06-30 Pfizer Products Inc. Ep2 agonists
EP2077826B1 (en) * 2006-10-20 2013-09-04 Children's Medical Center Corporation Method to enhance tissue regeneration
ES2545121T3 (en) * 2007-08-21 2015-09-08 Senomyx, Inc. Compounds that inhibit (block) the bitter taste in compositions, and use thereof
SI2264009T1 (en) * 2008-03-12 2019-05-31 Ube Industries, Ltd. Pyridylaminoacetic acid compound
WO2010096264A2 (en) 2009-02-03 2010-08-26 Children's Medical Center Corporation Methods for enhancing hematopoietic stem/progenitor cell engraftment
WO2010091052A2 (en) 2009-02-03 2010-08-12 Children's Medical Center Corporation Methods for enhancing hematopoietic stem/progenitor cell engraftment
HRP20160104T1 (en) 2009-03-30 2016-03-25 Ube Industries Pharmaceutical composition for treating or preventing glaucoma
WO2010116270A1 (en) 2009-04-10 2010-10-14 Pfizer Inc. Ep2/4 agonists
CN102498101A (en) * 2009-09-11 2012-06-13 宇部兴产株式会社 Aniline compounds
WO2011030871A1 (en) * 2009-09-11 2011-03-17 宇部興産株式会社 N-substituted heteroaryl compounds
JP2011057633A (en) * 2009-09-11 2011-03-24 Ube Industries Ltd Medicine containing pyridylaminoacetic acid compound
WO2011030865A1 (en) * 2009-09-11 2011-03-17 宇部興産株式会社 Substituted zenzyl compounds
WO2011030873A1 (en) * 2009-09-11 2011-03-17 宇部興産株式会社 Benzyl compounds
WO2011030868A1 (en) * 2009-09-11 2011-03-17 宇部興産株式会社 Substituted carbonyl compounds
WO2011030872A1 (en) * 2009-09-11 2011-03-17 宇部興産株式会社 Sulfonamide compounds
EP2520570A4 (en) * 2009-12-25 2013-07-17 Ube Industries AMINOPYRIDINE COMPOUND
CA2845284C (en) 2011-08-18 2018-03-06 Dr. Reddy's Laboratories Ltd. Substituted heterocyclic amine compounds as cholesteryl ester-transfer protein (cetp) inhibitors
CN103958511A (en) 2011-09-27 2014-07-30 雷迪博士实验室有限公司 5 - benzylaminomethyl - 6 - aminopyrazolo [3, 4 -b] pyridine derivatives as cholesteryl ester -transfer protein (cetp) inhibitors useful for the treatment of atherosclerosis
US10111907B2 (en) 2011-12-02 2018-10-30 Fate Therapeutics, Inc. Methods of treating ischemia
CN112375734A (en) 2011-12-02 2021-02-19 菲特治疗公司 Enhanced stem cell compositions
HK1210969A1 (en) * 2012-01-20 2016-05-13 奥克塞拉有限公司 Substituted heterocyclic compounds for disease treatment
JP2015537028A (en) * 2012-11-16 2015-12-24 アラーガン、インコーポレイテッドＡｌｌｅｒｇａｎ，Ｉｎｃｏｒｐｏｒａｔｅｄ Compositions and methods for skin repair
WO2014150602A1 (en) 2013-03-15 2014-09-25 Fate Therapeutics, Inc. Cell potency assay for therapeutic potential
EP2980075A4 (en) 2013-03-28 2016-08-10 Ube Industries SUBSTITUTED BIARYL COMPOUND
PT3143026T (en) 2014-05-13 2024-09-27 Novartis Ag Compounds and compositions for inducing chondrogenesis
CN106397149B (en) * 2016-08-26 2019-05-21 大连奇凯医药科技有限公司 The preparation method of pentafluorobenzaldehyde
CN115636761B (en) * 2021-07-20 2024-07-05 中国石油天然气股份有限公司 Oil-soluble surfactant, oil-displacing agent and application thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2113787A1 (en) * 1993-01-29 1994-07-30 Nobuyuki Hamanaka Carbocyclic sulfonamides
US6426359B1 (en) * 1996-12-20 2002-07-30 Pfizer Inc. Prevention and treatment of skeletal disorder with EP2 receptor subtype selective prostaglandin E2 agonists
UA67754C2 (en) * 1997-10-10 2004-07-15 Пфайзер, Інк. Prostaglandin agonists and use thereof for the treatment of bone disorders
US6376533B1 (en) * 2000-10-20 2002-04-23 Allergan Sales, Inc. Omega-cycloalkyl 17-heteroaryl prostaglandin E2 analogs as EP2-receptor agonists

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7196089B2 (en) 2003-01-29 2007-03-27 Asterand Uk Limited EP4 receptor antagonists
US7507754B2 (en) 2003-01-29 2009-03-24 Asterand Uk Limited EP4 receptor antagonists
US7417068B2 (en) 2003-10-16 2008-08-26 Asterand Uk Limited EP4 receptor antagonists
US7569602B2 (en) 2003-10-16 2009-08-04 Asterand Uk Limited Furan derivatives as EP4 receptor antagonists

Also Published As

Publication number Publication date
PL378748A1 (en) 2006-05-15
CN1859903A (en) 2006-11-08
MXPA05009398A (en) 2005-12-05
ZA200506532B (en) 2007-03-28
NZ541828A (en) 2008-06-30
JP2006519250A (en) 2006-08-24
BRPI0408061A (en) 2006-02-14
CA2518193A1 (en) 2004-09-16
TW200424176A (en) 2004-11-16
AU2004216898A1 (en) 2004-09-16
EP1601351A1 (en) 2005-12-07
CL2004000412A1 (en) 2005-02-04
WO2004078169A1 (en) 2004-09-16
KR20050105511A (en) 2005-11-04

Similar Documents

Publication Publication Date Title
WO2004078169A8 (en) Use of ep2 selective receptor agonists in medical treatment
Pugh et al. Advances in the management of humeral nonunion
WO2007120539A3 (en) Orthopedic device
WO2001050999A3 (en) Materials and methods for improved bone tendon bone transplantation
WO2009109778A3 (en) Implantable prosthetic cord
Masri et al. Seven specialized exposures for revision hip and knee replacement
BR0314362A (en) Method to prevent or reduce secondary fractures after hip fracture
Chen et al. Double-strut free vascular fibular grafting for reconstruction of the lower extremities
RU2006126967A (en) METHOD FOR ARTHRODESIS OF THE ANKLE AND TANTED JOINTS
Raja Gopal et al. Functional outcome of ante grade interlocking intramedullary nailing for humeral shaft fractures
KR101439944B1 (en) Tibial tuberosity advancement using hydroxyapatite scaffold in the small animal cranial cruciate ligament rupture
RU2000103308A (en) METHOD FOR OSTEOSYNTHESIS OF INJOINT JOINT COMPRESSION FROUSERS OF TYPO condyles under the control of arthroscopy
De Carolis et al. A lifelong story: Case report of a humeral shaft nonunion successfully treated after 30 years
RU2003112396A (en) METHOD FOR REHEDIATED HIP JOINT
RU2423085C2 (en) Method of endoprosthetics of hip joint in case of high congenital hip dislocation
Mathoulin et al. Scaphoid Nonunion: Surgical Fixation with Vascularized Bone Grafts–Volar Pedicle
RU2553509C1 (en) Method of single-step transiliac elongation of lower extremity
Low et al. Herbert screw fixation of scaphoid fractures
Ghauri et al. Simple plan of treatment for aseptic non-union of Diaphyseal Fractures of long bones
Magnan et al. Short and Long Term Results of Treatment
Beckenbaugh PIP joint surgery in rheumatoid disease
WO2004004663A3 (en) Compositions and methods for ligament growth and repair
RU2000101944A (en) METHOD FOR SURGICAL CORRECTION OF NEAR-JOINT DEFENSE OF KNEE JOINT IN CHILDREN
UA67551A (en) Method for surgical treatment of deforming arthrosis of the first metatarsophalangeal joint
MD2299F1 (en) Method of patella fractures osteosynthesis

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DPEN Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed from 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 1-2005-501597

Country of ref document: PH

WR Later publication of a revised version of an international search report
WWE Wipo information: entry into national phase

Ref document number: 2005/06532

Country of ref document: ZA

Ref document number: 200506532

Country of ref document: ZA

Ref document number: 541828

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 170380

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 2004216898

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2004713611

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2518193

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: PA/a/2005/009398

Country of ref document: MX

Ref document number: 1020057016414

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 2006506276

Country of ref document: JP

ENP Entry into the national phase

Ref document number: 2004216898

Country of ref document: AU

Date of ref document: 20040223

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2004216898

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 20048085767

Country of ref document: CN

WWP Wipo information: published in national office

Ref document number: 1020057016414

Country of ref document: KR

WWP Wipo information: published in national office

Ref document number: 2004713611

Country of ref document: EP

ENP Entry into the national phase

Ref document number: PI0408061

Country of ref document: BR